dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Ramos-Muntada, Mireia |
dc.contributor.author | Trincado Alonso, Juan Luis |
dc.contributor.author | Blanco, Joan |
dc.contributor.author | Bueno, Clara |
dc.contributor.author | Rodríguez Cortez, Virginia Carolina |
dc.contributor.author | Ortega Blanco, Margarita |
dc.contributor.author | VELASCO, PABLO |
dc.contributor.author | Bataller Torralba, Alex |
dc.date.accessioned | 2023-05-24T11:41:46Z |
dc.date.available | 2023-05-24T11:41:46Z |
dc.date.issued | 2022-08 |
dc.identifier.citation | Ramos-Muntada M, Trincado JL, Blanco J, Bueno C, Rodríguez-Cortez VC, Bataller A, et al. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia. Mol Oncol. 2022 Aug;16(16):2899–919. |
dc.identifier.issn | 1878-0261 |
dc.identifier.uri | https://hdl.handle.net/11351/9614 |
dc.description | Heterogeneïtat clonal; Modelatge computacional; Predictors de risc |
dc.description.sponsorship | The authors thank Anthony V Moorman (University of Newcastle, UK) and Francesc Solé (Josep Carreras Leukemia Research Institute) for critical discussions. Special thanks to Francisco Gutierrez-Agüera, Paola Romecín and Talía Velasco-Hernández (PM's lab) for technical help. We thank the CERCA program (Generalitat de Catalunya) and the Josep Carreras Foundation-Obra Social la Caixa for institutional support. This work is supported by the Spanish Ministry of Science and Innovation (PID2019-108160RB-I00/AEI/10.13039/501100011033, the European Research Council (CoG-2014-646903), the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R and SAF-2019-108160-R), the Leo Messi Foundation, the Health Institute Carlos III (ISCIII) (RICORS, RD21/0017/0029) within the Next Generation EU program (plan de recuperación, transformación y resilencia), and the Fundación Uno entre Cienmil (PM). Additional funding was provided by the ISCIII (FEDER PI17/01028 and PI20/00822) (CB), the Generalitat de Catalunya (2017/SGR-503) and the Universitat Autònoma de Barcelona (UAB/CF-180034) (JB) and the Blood Cancer UK (CJH). JLT was supported by a Juan de la Cierva fellowship by the Spanish Ministry of Science and Innovation (FJC2019-040868-I), BL-M was supported by the Asociación Española Contra el Cáncer (AECC; INVES20011LÓPE). AB was supported by the Fundación Española de Hematología y Hemoterapia (FEHH). OM was supported by a Beatriu de Pinós Postdoctoral Fellowship (BP2016-00048) from AGAUR (Generalitat de Catalunya), a 2017 Lady Tata Memorial Trust International Award, and the AECC (INVES211226MOLI). PM is an investigator of the Spanish Cell Therapy cooperative network (TERCEL). |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Molecular Oncology;16(16) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Infants |
dc.subject | Anomalies cromosòmiques |
dc.subject | Leucèmia limfoblàstica - Aspectes genètics |
dc.subject.mesh | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
dc.subject.mesh | /genetics |
dc.subject.mesh | Chromosome Aberrations |
dc.subject.mesh | Child |
dc.title | Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/1878-0261.13276 |
dc.subject.decs | leucemia-linfoma linfoblástico de células B precursoras |
dc.subject.decs | /genética |
dc.subject.decs | aberraciones cromosómicas |
dc.subject.decs | niño |
dc.relation.publishversion | https://doi.org/10.1002/1878-0261.13276 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Ramos-Muntada M, Blanco J] Cell Biology, Physiology and Immunology Department, Genetics of Male Fertility Group, Universitat Autonòma de Barcelona, Spain. [Trincado JL] Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain. CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Spain. Red Española de Terapias Avanzadas (TERAV), ISCIII, Barcelona, Spain. [Bueno C] Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain. Red Española de Terapias Avanzadas (TERAV), ISCIII, Barcelona, Spain. Centro de Investigacion Biomédica en Red de Cáncer (CIBER-ONC), ISCIII, Barcelona, Spain. [Rodríguez-Cortez VC] Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain. Red Española de Terapias Avanzadas (TERAV), ISCIII, Barcelona, Spain. [Bataller A] Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain. Red Española de Terapias Avanzadas (TERAV), ISCIII, Barcelona, Spain. Hematology Department, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Spain. [Ortega M] Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Velasco P] Servei d'Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 35726693 |
dc.identifier.wos | 000827314000001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |